A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

Scientists have discovered how aging blood stem cells acquire mutations that give them a growth edge, creating fertile ground for the development of clonol hematopoiesis, a condition that dramatically ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering n ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in ...

1Children’s Research Institute and the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas. 10Howard Hughes Medical Institute, UT Southwestern Medical Center, ...

Recent advancements in multi-omics technology have generated significant interest in exploring the role of gut microbiota in the treatment and prognosis of acute myeloid leukemia (AML ... function and ...

In 20 BTKi-experienced patients: 13 patients had change in tumor burden ... 1 CR and 4 PRs. TakeAim Leukemia In December 2024, the Company announced data from the TakeAim Leukemia study (NCT 04278768) ...